Free Trial
NASDAQ:INO

Inovio Pharmaceuticals (INO) Stock Price, News & Analysis

Inovio Pharmaceuticals logo
$2.44 -0.02 (-0.61%)
As of 03:42 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Inovio Pharmaceuticals Stock (NASDAQ:INO)

Key Stats

Today's Range
$2.34
$2.51
50-Day Range
$1.31
$2.46
52-Week Range
$1.30
$7.55
Volume
2.62 million shs
Average Volume
1.27 million shs
Market Capitalization
$129.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.80
Consensus Rating
Moderate Buy

Company Overview

Inovio Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

INO MarketRank™: 

Inovio Pharmaceuticals scored higher than 81% of companies evaluated by MarketBeat, and ranked 197th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inovio Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Inovio Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

  • Read more about Inovio Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Inovio Pharmaceuticals are expected to grow in the coming year, from ($4.23) to ($2.85) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inovio Pharmaceuticals is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inovio Pharmaceuticals is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Inovio Pharmaceuticals has a P/B Ratio of 4.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Inovio Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    10.09% of the float of Inovio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Inovio Pharmaceuticals has recently decreased by 14.86%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Inovio Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Inovio Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.09% of the float of Inovio Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Inovio Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Inovio Pharmaceuticals has recently decreased by 14.86%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Inovio Pharmaceuticals has a news sentiment score of 0.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Inovio Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    Only 2 people have searched for INO on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.
  • MarketBeat Follows

    12 people have added Inovio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Inovio Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.30% of the stock of Inovio Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    Only 26.79% of the stock of Inovio Pharmaceuticals is held by institutions.

  • Read more about Inovio Pharmaceuticals' insider trading history.
Receive INO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inovio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

INO Stock News Headlines

What Steve Bannon revealed about Trump’s gold play
A Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your IRA could be at risk. Here’s how to prepare.tc pixel
Inovio rises after promising Q2 results
See More Headlines

INO Stock Analysis - Frequently Asked Questions

Inovio Pharmaceuticals' stock was trading at $1.83 at the start of the year. Since then, INO shares have increased by 29.3% and is now trading at $2.3660.

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its quarterly earnings data on Tuesday, August, 12th. The biopharmaceutical company reported ($0.61) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.02.
Read the conference call transcript
.

Shares of Inovio Pharmaceuticals reverse split on the morning of Thursday, January 25th 2024.The 1-12 reverse split was announced on Thursday, January 25th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Top institutional shareholders of Inovio Pharmaceuticals include Bank of America Corp DE (3.46%), Geode Capital Management LLC (1.19%), Qube Research & Technologies Ltd (0.31%) and Bank of Montreal Can (0.16%).
View institutional ownership trends
.

Shares of INO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inovio Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Moderna (MRNA), Novavax (NVAX) and Pfizer (PFE).

Company Calendar

Last Earnings
8/12/2025
Today
8/28/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Medical Equipment
Current Symbol
NASDAQ:INO
CIK
1055726
Employees
320
Year Founded
1979

Price Target and Rating

High Price Target
$18.00
Low Price Target
$3.00
Potential Upside/Downside
+257.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.61)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$107.25 million
Net Margins
N/A
Pretax Margin
-48,220.33%
Return on Equity
-163.32%
Return on Assets
-96.41%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.66
Quick Ratio
1.66

Sales & Book Value

Annual Sales
$220 thousand
Price / Sales
594.20
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.54 per share
Price / Book
4.56

Miscellaneous

Outstanding Shares
53,140,000
Free Float
51,921,000
Market Cap
$130.72 million
Optionable
Optionable
Beta
1.38

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:INO) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners